Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Vistry Aktie bricht nach Gewinnwarnung und CFO-Abgang ein (Investing.com DE) +++ VISTRY Aktie -3,10%

CERVOMED Aktie

 >CERVOMED Aktienkurs 
2.27 EUR    (TradegateBSX)
Ask: 2.32 EUR / 1296 Stück
Bid: 2.22 EUR / 1400 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CERVOMED Aktie über LYNX handeln
>CERVOMED Performance
1 Woche: -4,7%
1 Monat: -28,0%
3 Monate: -29,8%
6 Monate: -45,5%
1 Jahr: -70,7%
laufendes Jahr: -66,6%
>CERVOMED Aktie
Name:  CERVOMED INC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US15713L1098 / A3ES01
Symbol/ Ticker:  DP8 (Frankfurt) / CRVO (NASDAQ)
Kürzel:  FRA:DP8, ETR:DP8, DP8:GR, NASDAQ:CRVO
Index:  -
Profil:  CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic and brain disorders. Headquartered in Boston, Massachusetts, CervoMed concentrates its efforts on central nervous system (CNS) disease..
>Volltext..
Marktkapitalisierung:  29.58 Mio. EUR
Unternehmenswert:  18.39 Mio. EUR
Umsatz:  1.81 Mio. EUR
EBITDA:  -26.99 Mio. EUR
Nettogewinn:  -26.06 Mio. EUR
Gewinn je Aktie:  -2.84 EUR
Schulden:  -
Liquide Mittel:  6.89 Mio. EUR
Operativer Cashflow:  -23.93 Mio. EUR
Bargeldquote:  2.87
Umsatzwachstum:  -78.99%
Gewinnwachstum:  -50.64%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  CERVOMED
Letzte Datenerhebung:  04.08.26
>CERVOMED Kennzahlen
Aktien/ Unternehmen:
Aktien: 13.53 Mio. St.
Frei handelbar: 59.94%
Rückkaufquote: -13.5%
Mitarbeiter: 15
Umsatz/Mitarb.: 0.23 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 673.35%
Bewertung:
KGV: -
KGV lG: -
KUV: 11.58
KBV: 2.22
PEG-Ratio: -0.02
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -1437.83%
Operative Marge: -1488.86%
Managementeffizenz:
Gesamtkaprendite: -111.89%
Eigenkaprendite: -132.76%
>CERVOMED Peer Group
Gesundheit, Demenz/ Alzheimer- Behandlung, Neurologische Erkrankungen/ Schlaganfälle
 
04.08.26 - 11:18
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) (GlobeNewswire EN)
 
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines...
14.07.26 - 13:33
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) (GlobeNewswire EN)
 
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)...
09.07.26 - 13:33
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia (GlobeNewswire EN)
 
Interim biomarker data accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference...
06.07.26 - 13:33
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer′s Association International Conference (AAIC) 2026 (GlobeNewswire EN)
 
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies...
22.06.26 - 22:09
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire EN)
 
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share....
18.06.26 - 18:39
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire EN)
 
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions....
18.06.26 - 14:30
Neues US-Patent treibt CervoMed Aktie um 20 % in die Höhe (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
18.06.26 - 13:03
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 (GlobeNewswire EN)
 
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, also known as “pure DLB”....
17.06.26 - 05:18
Top Biotech Gainers: CRVO On Watch, SLP Scooped Up, LNAI Back In Compliance, NTHI Advances NEO212 (RTTNews)
 
Tuesday's top gainers include CervoMed, with key clinical trial catalysts ahead; Conexeu, which strengthened its leadership with board expansion; NeOnc, advancing its lead drug candidate into Phase 2 for aggressive brain tumours; and Simulations Plus, which is set to be acquired by Altaris affiliates, among others....
16.06.26 - 15:24
Insiderkauf treibt CervoMed Aktie um 32 % (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
16.06.26 - 03:01
Insiderhandel: Aufsichtsrat kauft Aktien von CervoMed im Wert von 3000000 USD (Insiderkauf)
 
Boger, Joshua S. - Aufsichtsrat - Tag der Transaktion: 2026-06-11...
12.06.26 - 13:33
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire EN)
 
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026....
10.06.26 - 15:01
CervoMed-Aktie fällt um 15 % nach Ankündigung einer Finanzierung über 10,5 Mio. US-Dollar (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
18.05.26 - 13:45
CervoMed reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.05.26 - 13:33
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
 
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing...
22.04.26 - 13:33
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies (GlobeNewswire EN)
 
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible...
07.04.26 - 13:33
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting (GlobeNewswire EN)
 
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design...
19.03.26 - 12:33
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod′s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer′s Disease Co-Pathology (GlobeNewswire EN)
 
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial...
17.03.26 - 12:45
CervoMed reports FY results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wenn wir nur das Unrecht hassen und nicht diejenigen, die es tun, werden wir unsere Kampfgenossen und unsere Feinde lieben. - Freifrau Marie von Ebner-Eschenbach
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!